GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Shiller PE Ratio

IMMP (Immutep) Shiller PE Ratio : (As of Dec. 12, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Immutep Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Immutep Shiller PE Ratio Historical Data

The historical data trend for Immutep's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Shiller PE Ratio Chart

Immutep Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immutep Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immutep's Shiller PE Ratio

For the Biotechnology subindustry, Immutep's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Immutep's Shiller PE Ratio falls into.



Immutep Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Immutep's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, Immutep's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0/128.9064*128.9064
=0.000

Current CPI (Jun. 2024) = 128.9064.

Immutep Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200806 -0.179 85.071 -0.271
200906 -0.184 86.278 -0.275
201006 -0.782 88.971 -1.133
201106 -1.011 92.129 -1.415
201112 -0.772 92.686 -1.074
201206 -1.113 93.244 -1.539
201212 -0.651 94.730 -0.886
201306 -0.724 95.473 -0.978
201312 -0.430 97.330 -0.570
201406 -0.403 98.352 -0.528
201412 -0.412 99.002 -0.536
201506 -1.381 99.838 -1.783
201512 -2.026 100.673 -2.594
201603 -0.087 100.488 -0.112
201606 0.115 100.859 0.147
201612 -0.137 102.159 -0.173
201703 -0.081 102.624 -0.102
201706 -0.073 102.809 -0.092
201712 -0.127 104.110 -0.157
201806 -0.217 104.945 -0.267
201812 -0.198 105.967 -0.241
201906 -0.170 106.617 -0.206
201912 -0.100 107.917 -0.119
202006 -0.121 106.246 -0.147
202009 0.000 107.917 0.000
202012 -0.284 108.846 -0.336
202103 0.000 109.496 0.000
202106 -0.096 110.332 -0.112
202109 0.000 111.168 0.000
202112 -0.139 112.654 -0.159
202203 0.000 115.069 0.000
202206 -0.130 117.112 -0.143
202209 0.000 119.248 0.000
202212 -0.159 121.477 -0.169
202303 0.000 123.148 0.000
202306 -0.142 124.170 -0.147
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000
202403 0.000 127.606 0.000
202406 0.000 128.906 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Immutep  (NAS:IMMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Immutep Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Immutep's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep Business Description

Address
264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.